Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Prostate Cancer

Blood clot risk found among men with prostate cancer

Blood clots are very serious and need to be treated quickly.

The Independent UK

Fraser Coast's best dressed bikers suit up and ride off with an important message about prostate cancer

Are these the best-dressed bikies you've ever seen? They're revving their way through the Fraser Coast this weekend to raise awareness for prostate cancer.

ABC News

Early prostate cancer warning signs men should look out for

An expert has explained why and when you should see your GP

Liverpool Echo

From analysis to the latest developments in health,
read the most diverse news in one place.

NHS checks for prostate cancer hit all-time high

Some 550,000 people checked their risk of developing the disease online during the six weeks of a campaign.

The Independent UK

Wednesday headlines: Rangers fans 'attacked with glasses and flares Frankfurt ultras'

Here are the main headlines on the Daily Record website today.

Daily Record

Outlander's Sam Heughan will be motorbiking across Edinburgh this weekend to raise cash for charity

Sam will raise cash for men's mental health and prostate cancer research when he takes part in the Distinguished Gentlemen's Ride across the streets of Edinburgh this Sunday.

Daily Record

Sorrento Starts Mid-Stage Study Of Abivertinib In Prostate Cancer

The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ:SRNE) investigational new drug application (IND) for Abivertinib (Fujovee) for Phase 2 MAVERICK study in metastatic castrate-resistant prostate cancer (mCRPC). The MAVERICK study will be conducted in a partnership with the Prostate Cancer Clinical Trials Consortium and will enroll participants with both abiraterone-naïve and abiraterone-progressing…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Five signs of prostate cancer symptoms that men need to know

One in eight men will suffer from prostate cancer, according to charity figures

Liverpool Echo

What daily workout helps you lose weight? Researchers' new find helps dieters lose 4cm in 6 weeks

This comes as researchers from the University of Oxford found that larger waistlines increase the risk of prostate cancer

Daily Record

Early symptoms of prostate cancer men shouldn't ignore and the treatments available

The illness was brought into sharp focus last month when an Oscar-winning Hollywood actor died

Nottingham Post

Prostate cancer symptoms: Seven early warning signs from a weak flow to straining

Prostate cancer is the most common cancer in men, and the second most common cancer in the UK, according to National Institute for Health Care and Excellence (NICE). With this in mind, we take a look at seven early warning signs you should never ignore

Daily Mirror

Early telltale prostate cancer signs and symptoms that men should never ignore

One in eight men will suffer from the illness during their lifetime, according to charity figures.

Daily Record

Early symptoms of prostate cancer men need to watch out for

A doctor has explained why and when you should see your GP

Wales Online

Revolutionary new non-invasive prostate treatment is being rolled out across the UK

A new focal therapy that uses high focused beams of ultrasound or cryotherapy to target and treat the cancer leaving surrounding organs and tissue unharmed is set to offer a new lifeline

Daily Mirror

Get all your
news in one place.

100's of premium titles.
One news app.

Dublin Live

Fair City's Tommy O'Neill says it's a 'miracle' he's alive after being given months to live

The soap star - who plays Detective John Deegan - was told he had prostate cancer in 2020 and told he would be lucky to survive another 18 months

The Independent UK

New prostate cancer treatment using ultrasound rolling out across UK

One in eight men will be diagnosed with prostate cancer in their lifetime

Benzinga

Myovant, Accord Healthcare Ink Relugolix Distribution Pact For Europe In Prostate Cancer

Myovant Sciences Ltd (NYSE:MYOV) and Accord Healthcare Ltd have entered into an exclusive license agreement to commercialize Orgovyx (relugolix) for advanced hormone-sensitive prostate cancer in the European Economic Area, the U.K., Switzerland, and Turkey. Accord has the right to the first negotiation if Myovant decides to enter into licensing arrangements in countries in the Middle…

Wales Online

Revolutionary new non-invasive prostate treatment is being rolled out across the UK

A new focal therapy that uses high focused beams of ultrasound or cryotherapy to target and treat the cancer leaving surrounding organs and tissue unharmed is set to offer a new lifeline

Get all your
news in one place.

100's of premium titles.
One news app.

Daily Record

Male weight loss could slash prostate cancer deaths according to new study

Findings show that prostate cancer deaths could reduce significantly if less men were overweight

Motorsport

Lowndes to race prostate cancer Porsche at Bathurst

Craig Lowndes will spearhead the driver line-up for a Porsche that will promote the Prostate Cancer Foundation of Australia at the Bathurst 12 Hour.

The Independent UK

1,300 prostate cancer deaths could be prevented if men lose weight – study

Having a higher BMI and a larger waistline has been linked to a higher risk of death from prostate cancer.

Wales Online

1,300 prostate cancer deaths could be prevented if men lose weight - study

Experts are starting to unpick the link between prostate cancer and weight

Tribune News Service

Bryce Miller: How and why Steve Lavin wound up coaching basketball in San Diego

SAN DIEGO — In a horseshoe-shaped booth at bustling Manhattan of La Jolla, Steve Lavin used the better part of 3 1/2 hours to explore the people who have influenced his life, being a 32-year-old college basketball coach under the withering spotlight at UCLA, the prostate cancer that reconfigured perspective…

Benzinga

Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer

Myovant Sciences Ltd (NYSE:MYOV) received European approval for Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer, and SVB Securities think Orgovyx could be a ~$1 billion product in advanced prostate cancer long term. But the surprise Myfembree setback in endometriosis has sparked uncertainty and new investor questions for Myovant's 2nd program. Hence, SVB remains on the…

Benzinga

Myovant Sciences' Relugolix For Hormone-Sensitive Prostate Cancer Approved In Europe

The European Commission (EC) has approved Myovant Sciences Ltd's (NYSE:MYOV) Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer. This approval was supported by data from the Phase 3 HERO study. In the HERO study, Orgovyx met the primary endpoint and achieved sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48…

1 … 37 38 39 40

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.